Infectious Diseases in Critical Care Medicine

16. Centers for Disease Control. Draft guide C, part 1: infection control measures for healthcare and
    community settings. Available at: http://www.bt.cdc.gov/agents/smallpox/response-plan/files/
    guide-c-part-1.pdf. Accessed on July 10, 2008.


17. Grabenstein JD. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008;
    46:129–136.


18. Mann JS, Douglas JG, Inglis JM, et al. Q fever: person-to-person transmission within a family. Thorax
    1986; 41:974–975.


19. Santic ́Z, Santic ́Z, Demirovic ́M. A familial epidemic of Q-fever in Herzegovina. Med Arh 1985;
    39:33–36.


20. Hughes C, Maharg P, Rosario P, et al. Possible nosocomial transmission of psittacosis. Infect Control
    Hosp Epidemiol 1997; 18:165–168.


21. Bourke SJ, Carrington D, Frew CE, et al. Serological cross-reactivity among chlamydial strains in a
    family outbreak of psittacosis. J Infect 1989; 19:41–45.


22. Learned LA, Reynolds MG, Wassa DW, et al. Extended interhuman transmission of monkeypox in a
    hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 2005; 73:428–434.


23. Kyriacou DN, Adamski A, Khardori N. Anthrax: from antiquity and obscurity to a front-runner in
    bioterrorism. Infect Dis Clin North Am 2006; 20:227–251.


24. APIC—Association for Professionals in Infection Control & Epidemiology. Bioterrorist agents—
    watch for these symptoms. Available at: http://www.apic.org/bioterror/. Accessed on July 11,
    2008.


25. Cleri DJ, Marton R, Rabbat M, et al. Chapter 49. Pneumonia caused byYersinia pestisPlague
    pneumonia. In: Marrie TJ, ed. Community Acquired Pneumonia. New York, NY: Kluwer
    Academic/Plenum Publishers; 2001:777–799.


26. Cook LD, Tempest B. Plague. A clinical review of 27 cases. Arch Intern Med 1992; 152:1253–1256.


27. Cleri DJ. Anthrax Primer. Health Studies Institute; 2001:1–2.


28. Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential
    for bioterrorism. Infect Dis Clin North Am 2006; 20:313–327.


29. Koirala J. Plague disease, management, and recognition of act of terrorism. Infect Dis Clin North Am
    2006; 20:273–287.


30. Eliasson H, Broman T, Forsman M, et al. Tularemia: current epidemiology and disease management.
    Infect Dis Clin North Am 2006; 20:289–311.


31. Dance DAB. Melioidosis. In: Guerrand RL, Walker DH, Weller PF, eds. Tropical Infectious Diseases,
    Principles, Pathogens and Practice. Vol 2. 2nd ed. Philadelphia, PA: Churchill Livingston Elsevier;
    2006:381–388.


32. Nausheen S, Cunha BA. Q fever community-acquired pneumonia in a patient with Crohn’s disease
    on immunosuppressive therapy. Heart Lung 2007; 36:300–303.


33. Wong J, Korcheva V, Jacoby DB, et al. Intrapulmonary delivery of ricin at high dosage triggers a
    systemic inflammatory response and glomerular damage. Am J Pathol 2007; 170:1497–1510.


34. Raoult D, Walker DH.Rickettsia prowazekii(epidemic or louse-borne typhus). In: Mandell GL,
    Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 2. 6th ed. Philadelphia:
    Churchill Livingston Elsevier; 2005:2303–2306.


35. Reynolds MG, Davidson WB, Curns AT, et al. Spectrum of infection and risk factors for human
    monkeypox. United States, 2003. Emerg Infect Dis 2007; 13:1332–1339.


36. Reynolds MG, Yorita KL, Kuehnert MJ, et al. Clinical manifestations of human monkeypox
    influenced by route of infection. J Infect Dis 2006; 194:773–780.


37. Giriputro S, Agus R, Sulastri S, et al. Clinical and epidemiological features of patients with
    confirmed avian influenza presenting to Suilanti Saroso Infectious Diseases Hospital, Indonesia,
    2005–2007. Ann Acad Med Singapore 2008; 37:454–457.


38. Bartlett JG. The Jeremiah Metzger lecture: avian influenza. Trans Am Clin Climatol Assoc 2006;
    117:285–295.


39. Chen YC, Chang SC, Tsai KS, et al. Certainties and uncertainties facing emerging respiratory
    infectious diseases: lessons from SARS. J Formos Med Assoc 2008; 107:432–442.


40. Li J, Loeb JA, Shy ME, et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West
    Nile virus infection. Ann Neurol 2003; 53:703–710.


41. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus
    infection. JAMA 2003; 290:511–515.


42. Munckhof WJ, Runnegar N, Gray TJ, et al. Two rare severe and fulminant presentations of Q fever in
    patients with minimal risk factors for this disease. Intern Med J 2007; 37:775–778.


43. Kyriacou DN, Yarnold PR, Stein AC, et al. Discriminating inhalational anthrax from community-
    acquired pneumonia using chest radiograph findings and a clinical algorithm. Chest 2007;
    131:489–496.

Bioterrorism Infections in Critical Care 483